Background. TLR ligands can promote Th1-biased immune responses, mimicking potent stimuli of viruses and bacteria. Aim. To\ninvestigate the adjuvant properties of dual TLR2/7 ligands compared to those of the mixture of both single ligands. Methods.\nDual TLR2/7 ligands: CL401, CL413, and CL531, including CL264 (TLR7-ligand) and Pam2CysK4 (TLR2-ligand), were used.\nImmune-modulatory capacity of the dual ligands with the individual ligands alone or as a mixture in mouse BMmDCs,\nBMmDC:TC cocultures, or BMCMCs was compared and assessed in na�¯ve mice and in a mouse model of OVA-induced\nintestinal allergy. Results. CL413 and CL531 induced BMmDC-derived IL-10 secretion, suppressed rOVA-induced IL-5 secretion\nfrom OVA-specific DO11.10 CD4+ TCs, and induced proinflammatory cytokine secretion in vivo. In contrast, CL401 induced\nconsiderably less IL-10 secretion and led to IL-17A production in BMmDC:TC cocultures, but not BMCMC IL-6 secretion, or\nIL-6 or TNF-�± production in vivo. No immune-modulating effects were observed with single ligands. All dual TLR2/7 ligands\nsuppressed DNP-induced IgE-and-Ag-specific mast cell degranulation. Compared to vaccination with OVA, vaccination with\nthe mixture CL531 and OVA, significantly suppressed OVA-specific IgE production in the intestinal allergy model. Conclusions.\nBased on beneficial immune-modulating properties, CL413 and CL531 may have utility as potential adjuvants for allergy treatment.
Loading....